Clinical Trials
12 trialsNCT03764540 2025-04-13
CABPOSTAAT
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02478502 2024-02-02
Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer
University Hospital, Akershus
Phase 2 Terminated
NCT01650285 2022-03-04
Cabazitaxel and Radiation For Patients With Prostate Cancer
Brown University
Phase 2 Terminated
NCT02844582 2021-01-25
Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
University of California, Davis
Phase 2 Terminated
NCT03043989 2020-02-17
Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT02379390 2019-06-21
PRIMCAB
Sanofi
Phase 2 Terminated
NCT01335204 2018-07-13
Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
Medical University of South Carolina
Phase 1/2 Terminated
NCT01845792 2018-06-04
Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer
University of Colorado, Denver
Phase 2 Terminated
NCT01083615 2016-10-12
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Achieve Life Sciences
Phase 3 Terminated
NCT01469338 2014-11-24
Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
University of Southern California
Phase 2 Terminated
NCT01531205 2014-11-05
Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated